BUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌

路透中文

Mar 25

BUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌

3月25日 - ** 生物技术公司 Anavex Life Sciences AVXL.O 股价盘前下跌 18% 至 3.43 美元

** 该公司称已撤回其阿尔茨海默氏症实验性药物blarcamesine的欧盟申请，因为监管机构称他们无法支持批准该药物

** 公司称，欧洲药品管理局委员会表示无法对该药物作为早期患者的附加治疗给予肯定意见

** Anavex表示将收集更多数据并进行进一步分析，以解决监管机构提出的问题

** 该公司表示，该药物尚未在任何地方获得批准，仍处于开发阶段

** 阿尔茨海默氏症是最常见的痴呆症，是一种影响记忆和思维的疾病，主要发生在老年人身上

** 2025 年股价下跌约 67%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2622784660"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622784660\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622784660?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-25 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622784660","market":"us","top_or_hot":-1,"title":"BUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌</title></head><body><p><span>3月25日</span><span> - </span>** <a href=\"https://laohu8.com/S/000504\">生物</a>技术公司 <a href=\"https://laohu8.com/S/AVXL\">Anavex Life</a> Sciences <span>AVXL.O</span> 股价盘前下跌 18% 至 3.43 美元</p><p>** 该公司称已撤回其阿尔茨海默氏症实验性药物blarcamesine的欧盟申请，因为监管机构称他们无法支持批准该药物</p><p>** 公司称，欧洲药品管理局委员会表示无法对该药物作为早期患者的附加治疗给予肯定意见</p><p>** Anavex表示将收集更多数据并进行进一步分析，以解决监管机构提出的问题</p><p>** 该公司表示，该药物尚未在任何地方获得批准，仍处于开发阶段</p><p>** 阿尔茨海默氏症是最常见的痴呆症，是一种影响记忆和思维的疾病，主要发生在老年人身上</p><p>** 2025 年股价下跌约 67%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-25 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌</title></head><body><p><span>3月25日</span><span> - </span>** <a href=\"https://laohu8.com/S/000504\">生物</a>技术公司 <a href=\"https://laohu8.com/S/AVXL\">Anavex Life</a> Sciences <span>AVXL.O</span> 股价盘前下跌 18% 至 3.43 美元</p><p>** 该公司称已撤回其阿尔茨海默氏症实验性药物blarcamesine的欧盟申请，因为监管机构称他们无法支持批准该药物</p><p>** 公司称，欧洲药品管理局委员会表示无法对该药物作为早期患者的附加治疗给予肯定意见</p><p>** Anavex表示将收集更多数据并进行进一步分析，以解决监管机构提出的问题</p><p>** 该公司表示，该药物尚未在任何地方获得批准，仍处于开发阶段</p><p>** 阿尔茨海默氏症是最常见的痴呆症，是一种影响记忆和思维的疾病，主要发生在老年人身上</p><p>** 2025 年股价下跌约 67%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D13C:1","article_id":"2622784660","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622784660","pubTimestamp":1774439258,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","AVXL":"Anavex Life Sciences Corp."},"translate_title":"BUZZ-Anavex shares fall as it withdraws EU application for Alzheimer's drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":0.9},"content_text":"BUZZ-Anavex 撤回阿尔茨海默氏症药物的欧盟申请，股价下跌3月25日 - ** 生物技术公司 Anavex Life Sciences AVXL.O 股价盘前下跌 18% 至 3.43 美元** 该公司称已撤回其阿尔茨海默氏症实验性药物blarcamesine的欧盟申请，因为监管机构称他们无法支持批准该药物** 公司称，欧洲药品管理局委员会表示无法对该药物作为早期患者的附加治疗给予肯定意见** Anavex表示将收集更多数据并进行进一步分析，以解决监管机构提出的问题** 该公司表示，该药物尚未在任何地方获得批准，仍处于开发阶段** 阿尔茨海默氏症是最常见的痴呆症，是一种影响记忆和思维的疾病，主要发生在老年人身上** 2025 年股价下跌约 67%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}